Skip to content

Evaluating the Effectiveness of Iranian medicine product Compared to Solifenacin for Urgency Urinary Incontinence and Quality of Life in Women

Evaluating the Effectiveness of Iranian medicine product Compared to Solifenacin for Urgency Urinary Incontinence and Quality of Life in Women

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251110067942N1
Enrollment
66
Registered
2026-01-01
Start date
2025-12-22
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urgency Urinary Incontinence. Urge incontinence

Interventions

Intervention 1: Intervention group:The intervention group consumed 10 cc of persian medicine syrup in the evenings and one placebo tablet at night before bed for four weeks. The Persian medicine syrup

Sponsors

Ghoum University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Women who, according to the standardized questionnaire for Iran (QUID), suffer from urge urinary incontinence. At least two weeks must have passed since the discontinuation of any medication for controlling incontinence symptoms. Women who have signed the ethical informed consent form.

Exclusion criteria

Exclusion criteria: Active or recurrent urinary tract infection Uncontrolled diabetes or hyperglycemia BMI greater than 30 Severe heart disease and arrhythmia History of any neurological disease, such as Multiple Sclerosis (MS) History of uncontrolled severe asthma and allergies Post-void residual urine volume greater than 100 cc Presence of any pelvic organ prolapse Severe hepatic or renal diseases History of pelvic surgery within the past year Contraindication to anticholinergic medications Uncontrolled hypertension hematuria and vaginal bleeding Previous or active cancer of bladder Chronic bladder pain or dysuria History of pelvic surgery

Design outcomes

Primary

MeasureTime frame
Urinary incontinence score in the International Consultation on Incontinence Modular Questionnaire. Timepoint: Urinary incontinence measurements at baseline, 28, and 56 days after starting medication. Method of measurement: International Consultation on Incontinence Modular Questionnaire-Urinary Incontinence Short Form questionnaire.

Secondary

MeasureTime frame
Quality of life score. Timepoint: At the beginning of the study, 28 and 56 days after starting medication. Method of measurement: Incontinence Quality of Life Questionnaire (I-QOL).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam karimkhanizand

Ghoum University of Medical Sciences

Dr.karimkhanizand@gmail.com+98 25 3776 4073

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026